Welcome back to your second instalment for ‘Weed Week’.
Just as a quick recap, we’ve hijacked Money Morning this week. Well, it’s not a complete hijack. We do regularly write in Money Morning each week.
And you’ll occasionally see us write about medical cannabis. But this week we begged our managing editor to give us the whole week to focus on the huge opportunity of medical cannabis.
We know some people really think it’s the ‘devil’s lettuce’. And we know that hard line opposition think it’s a ‘gateway drug’ to the likes of heroin or cocaine.
But that couldn’t be further from the truth.
What a lot of people don’t understand is that our biology is built to respond to cannabis.
It’s a human condition
The human endocannabinoid system is connected to the central nervous system. It’s understood that the endocannabinoid system helps regulate physiological and cognitive processes such as:
- Pre and post-natal development
- Pain sensation
It’s this endocannabinoid system (that we all have) that scientists believe medicinal cannabis can influence. They believe the use of certain strains of cannabis we can treat and maybe cure illnesses and disease.
The research and development (R&D) in cannabis is astonishing. And we’re now seeing more clinical trials. Companies testing the effects of cannabis on human patients in regulated trials. It’s legitimate medical research.
For example, cannabis giant Canopy Growth Corp [TSE:WEED] had a huge announcement this week. It was focused on their own clinical trials:
‘Marking a major milestone for medical cannabis in Canada, a Phase IIb “in-human” clinical trial application was submitted by Canopy Health Innovations Inc. to evaluate the use of medical cannabis in the treatment of insomnia. Having received approval to proceed with these clinical trials in the form of a No Objection Letter (NOL) from Health Canada, Canopy Health will now proceed with these robust clinical trials, in collaboration with a leading Canadian research institution.’
It’s believed around one in three people globally suffer from a form of insomnia. Furthermore it’s believed around 90% of people who suffer depression also suffer insomnia. And people who suffer from sleep deprivation are 27% more likely to be obese or overweight.
Then there’s the financial cost. In the US alone insomnia costs the government more than US$15 billion per year in health care. And US industry loses around US$150 billion each year because of sleep-deprived workers.
If these clinical trials prove effective, we could be looking at real impact to global GDP. Imagine that…
Natural cannabis-based insomnia treatments. Potentially saving hundreds of billions of dollars.
That’s the kind of impact R&D into cannabis can deliver.
It’s why you must always look beyond preconceptions. You must look under the hood to see what’s really going on.
WHO says it’s good
Clinical trials are one thing. But when the World Health Organisation gets behind cannabis too, then you know the real heavy hitters are lining up.
Last week the WHO met for the first time to review the health and safety of cannabis.
According to Leafly:
‘As part of the report, the agency surveyed 953 cannabis patients from 31 countries. Most said they’d been using cannabis-based medicines for several years and are currently being advised on treatment by a doctor, although a majority said they’d also tried cannabis prior to getting a physician’s recommendation.’
Furthermore their research concluded:
- ‘Clinical trials have shown cannabis to be an effective analgesic for chronic pain. The results indicated that vaping cannabis reduced neuropathic pain and pain associated with diabetic peripheral neuropathy.
- ‘Cannabis oil containing THC can be beneficial for patients suffering from dementia, motor neuron disease, and neurogenic issues such as bladder control problems and muscle spasms.
- ‘Considerable evidence suggest that cannabis and specific cannabinoids are effective at relieving nausea and vomiting due to chemotherapy.’
Now let’s just remember this isn’t some cannabis company’s sponsored research. It’s the World Health Organisation.
Support from WHO is crucial. It will bring down the cannabis barriers. Prohibition has made it hard to research cannabis. That’s changing.
As countries begin to open their borders it will bring smart money.
The more R&D, the more investment, the more we learn about cannabis the more it all flows. This becomes a virtuous cycle.
It becomes a full medical industry. At that point the giants of cannabis will already be dominant. Companies like Canopy Growth will have a stranglehold on global, legal cannabis trade.
Then, as clinical trials complete big pharma will perk up and take notice.
We expect that serious R&D spending will begin to flow. And it may come from the biggest companies in the world. Companies like Johnson & Johnson, Merck, and Pfizer will come.
The play here is a biotech play. It’s medical research. Clinical trials. All the things you’d expect from a huge global biotech boom. And that’s exactly what’s happening.
Sam Volkering, Editor, Secret Crypto Network